PegBio-B (02565) has been included in the Hang Seng Composite Index and is expected to become a target for Stock Connect.

PegBio-B (02565) has been included in the Hang Seng Composite Index.

Zhitong FinanceFeb 13 19:24

IPO News | New Life Pharmaceuticals, Winged Robot Technology, and others have received material acceptance from the China Securities Regulatory Commission for their proposed Hong Kong IPOs.

New Ji Pharmaceutical, Yi Fei Technology, and others have had their materials for a proposed Hong Kong IPO received by the China Securities Regulatory Commission.

Zhitong FinanceJan 30 20:24

PegBio recently received a notice from cornerstone investors voluntarily extending the lock-up period.

PegBio-B (02565) surged over 6%. As of the time of writing, it was up 5.94%, trading at HKD 65.95, with a turnover of HKD 5.0822 million.

Zhitong FinanceDec 24, 2025 11:05

GLP-1 Agonists (Ozempic, Wegovy, Mounjaro) Market - Global Forecast to 2033: With the Semaglutide Patent Expiring in 2026 Onwards, the Biosimilars Market Is Expected to Grow Significantly

Yahoo FinanceDec 23, 2025 17:24

PegBio Formalizes Board Nomination Committee to Bolster Corporate Governance

TipRanksDec 23, 2025 16:39

PeptiDream Biopharma-B (02565.HK) has completed the placement of a total of 5.136 million shares.

Gelonghui December 22nd丨PegBio-B (02565.HK) announces that the Board is pleased to declare that all conditions of the placing agreement have been fulfilled, and the placing was completed on December 22, 2025. Pursuant to the terms and conditions of the placing agreement, the joint placing agents have placed a total of 5,136,000 placing shares with no fewer than six placees at a price of HKD 58.41 per placing share. This represents approximately 1.81% of the enlarged issued H-share capital immediately following the completion of the placing, and approximately 1.31% of the total number of shares.

Gelonghui FinanceDec 22, 2025 20:58